title: [Combined use of pyronaridine, sulfadoxine and primaquine in areas with chloroquine-resistant falciparum malaria].
authors.forename: L G
authors.initials: LG
authors.lastname: Che
authors.forename: K G
authors.initials: KG
authors.lastname: Huang
authors.forename: H L
authors.initials: HL
authors.lastname: Yang
authors.forename: L
authors.initials: L
authors.lastname: Yu
authors.forename: Z L
authors.initials: ZL
authors.lastname: Lin
authors.forename: R
authors.initials: R
authors.lastname: Huang
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D002738:Chloroquine / Q000494:pharmacology; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D009287:Naphthyridines / Q000008:administration & dosage*; D010963:Plasmodium falciparum / Q000187:drug effects; D011319:Primaquine / Q000008:administration & dosage*; D013413:Sulfadoxine / Q000008:administration & dosage*; D013424:Sulfanilamides / Q000008:administration & dosage*
chemical_list: D000962:Antimalarials; D009287:Naphthyridines; D013424:Sulfanilamides; D013413:Sulfadoxine; D002738:Chloroquine; D011319:Primaquine; C027871:pyronaridine